用于胰腺导管腺癌联合治疗的纳米载体：综述

Nanocarriers for Combination Therapy in Pancreatic Ductal Adenocarcinoma: A Comprehensive Review.

作者信息

Pontón Iris, Sánchez-García David

机构信息

Grup d'Enginyeria de Materials (GEMAT), Institut Químic de Sarrià (IQS), Universitat Ramon Llull (URL), Via Augusta 390, 08017 Barcelona, Spain.

出版信息

Nanomaterials (Basel). 2025 Jul 22;15(15):1139. doi: 10.3390/nano15151139.

DOI:10.3390/nano15151139

PMID:40801679

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12348418/

Abstract

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers worldwide, characterized by late diagnosis, aggressive progression, and poor response to conventional monotherapies. Combination therapies have emerged as a promising approach to overcome multidrug resistance (MDR), enhance efficacy, and target the complex tumor microenvironment (TME). Nanoparticle-based drug delivery systems (DDSs) have gained significant attention for their ability to co-deliver multiple agents with controlled release profiles. This review comprehensively examines nanoparticle-based platforms developed for PDAC combination therapies, focusing on small-molecule drugs. The systems discussed are drawn from studies published between 2005 and 2025.

摘要

胰腺导管腺癌（PDAC）仍然是全球最致命的癌症之一，其特点是诊断晚、进展迅速且对传统单一疗法反应不佳。联合疗法已成为一种有前景的方法，用于克服多药耐药性（MDR）、提高疗效并靶向复杂的肿瘤微环境（TME）。基于纳米颗粒的药物递送系统（DDS）因其能够以控释方式共同递送多种药物而备受关注。本综述全面研究了为PDAC联合疗法开发的基于纳米颗粒的平台，重点关注小分子药物。所讨论的系统来自2005年至2025年发表的研究。